These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 17162990)

  • 1. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings.
    Oka Y; Inoue Y; Kanbayashi T; Kuroda K; Miyamoto M; Miyamoto T; Ikeda A; Shimizu T; Hishikawa Y; Shibasaki H
    Sleep; 2006 Nov; 29(11):1439-43. PubMed ID: 17162990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness.
    Hong SC; Lin L; Jeong JH; Shin YK; Han JH; Lee JH; Lee SP; Zhang J; Einen M; Mignot E
    Sleep; 2006 Nov; 29(11):1429-38. PubMed ID: 17162989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
    Mignot E; Lammers GJ; Ripley B; Okun M; Nevsimalova S; Overeem S; Vankova J; Black J; Harsh J; Bassetti C; Schrader H; Nishino S
    Arch Neurol; 2002 Oct; 59(10):1553-62. PubMed ID: 12374492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.
    Andlauer O; Moore H; Hong SC; Dauvilliers Y; Kanbayashi T; Nishino S; Han F; Silber MH; Rico T; Einen M; Kornum BR; Jennum P; Knudsen S; Nevsimalova S; Poli F; Plazzi G; Mignot E
    Sleep; 2012 Sep; 35(9):1247-55F. PubMed ID: 22942503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population.
    Knudsen S; Jennum PJ; Alving J; Sheikh SP; Gammeltoft S
    Sleep; 2010 Feb; 33(2):169-76. PubMed ID: 20175400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A).
    Bassetti C; Gugger M; Bischof M; Mathis J; Sturzenegger C; Werth E; Radanov B; Ripley B; Nishino S; Mignot E
    Sleep Med; 2003 Jan; 4(1):7-12. PubMed ID: 14592354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency.
    Andlauer O; Moore H; Jouhier L; Drake C; Peppard PE; Han F; Hong SC; Poli F; Plazzi G; O'Hara R; Haffen E; Roth T; Young T; Mignot E
    JAMA Neurol; 2013 Jul; 70(7):891-902. PubMed ID: 23649748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy.
    Baumann CR; Khatami R; Werth E; Bassetti CL
    J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):402-4. PubMed ID: 16484654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DQB1 allele and hypocretin in Korean narcoleptics with cataplexy.
    Jeong JH; Hong SC; Shin YK; Han JH; Lee SP
    J Korean Med Sci; 2007 Feb; 22(1):127-31. PubMed ID: 17297265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Traditional biomarkers in narcolepsy: experience of a Brazilian sleep centre.
    Coelho FM; Pradella-Hallinan M; Pedrazzoli M; Soares CA; Fernandes GB; Gonçalves AL; Tufik S; Bittencourt LR
    Arq Neuropsiquiatr; 2010 Oct; 68(5):712-5. PubMed ID: 21049180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.
    Nishino S; Sakurai E; Nevsimalova S; Yoshida Y; Watanabe T; Yanai K; Mignot E
    Sleep; 2009 Feb; 32(2):175-80. PubMed ID: 19238804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
    Nishino S; Kanbayashi T
    Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway.
    Heier MS; Evsiukova T; Vilming S; Gjerstad MD; Schrader H; Gautvik K
    Sleep; 2007 Aug; 30(8):969-73. PubMed ID: 17702265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status.
    Krahn LE; Pankratz VS; Oliver L; Boeve BF; Silber MH
    Sleep; 2002 Nov; 25(7):733-6. PubMed ID: 12405608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between clinical characteristics of narcolepsy and CSF orexin-A levels.
    Nakamura M; Kanbayashi T; Sugiura T; Inoue Y
    J Sleep Res; 2011 Mar; 20(1 Pt 1):45-9. PubMed ID: 20642748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative analysis of patients with narcolepsy-cataplexy, narcolepsy without cataplexy and idiopathic hypersomnia].
    Martínez-Rodríguez JE; Iranzo A; Casamitjana R; Graus F; Santamaria J
    Med Clin (Barc); 2007 Mar; 128(10):361-4. PubMed ID: 17386240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypocretin and human African trypanosomiasis.
    Dauvilliers Y; Bisser S; Chapotot F; Vatunga G; Cespuglio R; Josenando T; Buguet A
    Sleep; 2008 Mar; 31(3):348-54. PubMed ID: 18363311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia.
    Kanbayashi T; Inoue Y; Chiba S; Aizawa R; Saito Y; Tsukamoto H; Fujii Y; Nishino S; Shimizu T
    J Sleep Res; 2002 Mar; 11(1):91-3. PubMed ID: 11869432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome.
    Kanbayashi T; Kodama T; Kondo H; Satoh S; Inoue Y; Chiba S; Shimizu T; Nishino S
    Sleep; 2009 Feb; 32(2):181-7. PubMed ID: 19238805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable CSF level of orexin A (hypocretin-1) in a HLA-DR2 negative patient with narcolepsy-cataplexy.
    Dalal MA; Schuld A; Pollmächer T
    J Sleep Res; 2002 Sep; 11(3):273. PubMed ID: 12220324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 37.